All the contributors belong to both TH and OMIMR.
Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer
Article first published online: 16 SEP 2010
© 2010 The Japan Society of Hepatology
Volume 40, Issue 12, pages 1168–1175, December 2010
How to Cite
Ikeda, K., Kobayashi, M., Seko, Y., Imai, N., Hirakawa, M., Kawamura, Y., Sezaki, H., Hosaka, T., Akuta, N., Saitoh, S., Suzuki, F., Suzuki, Y., Arase, Y. and Kumada, H. (2010), Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. Hepatology Research, 40: 1168–1175. doi: 10.1111/j.1872-034X.2010.00720.x
- Issue published online: 2 DEC 2010
- Article first published online: 16 SEP 2010
- Received 13 April 2010; revision 11 July 2010; accepted 14 July 2010.
- hepatitis C;
- hepatocellular carcinoma;
Background: Since hepatocellular carcinoma often recurs after surgical resection or radiofrequency ablation, we analyzed a retrospective large cohort of patients with small hepatocellular carcinoma caused by hepatitis C virus (HCV).
Methods: Among 379 patients with HCV RNA-positive small hepatocellular carcinoma (multiple up to three nodules, 3 cm or less each), 77 received interferon-alpha injection and 302 received no anti-viral therapy.
Results: Four patients (5.2%) attained sustained virological response (SVR). Cumulative recurrence rates in the treated and untreated groups were 41.1% and 57.5% at the end of the third year, and 63.0% and 74.5% at the fifth year, respectively (P = 0.013). Fifth year-recurrence rates in treated group were 25.0% in SVR, 85.7% in biochemical response, 71.1% in no response, and 46.7% in patients with continuous administration. When four patients with SVR were excluded, recurrence rates in short-term interferon therapy (<2 years) and long-term therapy (≥2 years) were 46.2% and 39.3% at the third year, and 66.2% and 57.4% at the fifth year, respectively (P = 0.012). Multivariate analysis showed that long-term interferon therapy significantly decreased recurrence rate (hazard ratio for interferon <2 years 0.80, interferon ≥2 years 0.60, P = 0.044), after adjustment with background covariates including indocyanine green retention rate (P = 0.018), alpha-fetoprotein (P = 0.051), and tumor treatment (P = 0.066).
Conclusion: A long-term administration of low-dose interferon significantly decreased recurrence of hepatocellular carcinoma after surgical resection or radiofrequency ablation.